Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI

J Musculoskelet Neuronal Interact. 2018 Mar 1;18(1):76-80.

Abstract

Children with osteogenesis imperfecta (OI) type VI often have high fracture rates despite the current standard treatment with bisphosphonates. Subcutaneous injections of denosumab have been proposed as an alternative treatment approach, but safety data on denosumab in children are limited. Here we describe fluctuations in bone and mineral metabolism during denosumab treatment in four children with OI type VI who started denosumab (basic protocol: 1 mg per kg body mass every 3 months) between 1.9 and 9.0 years of age, after having received intravenous bisphosphonates previously. All four children developed hypercalciuria during active denosumab therapy. In two children aged 3.9 and 4.6 years, episodes of hypercalcemia were observed between 7 and 12 weeks after the preceding denosumab injection. During times when the interval between denosumab injections was increased to 6 months for clinical reasons, lumbar spine bone mineral density z-scores decreased rapidly. It appears that the duration of action of denosumab is short and variable in children with OI type VI. These observations call into question the concept that denosumab can be used as a stand-alone alternative to bisphosphonates to treat children with OI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Density / drug effects*
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / adverse effects*
  • Bone Density Conservation Agents / therapeutic use
  • Child
  • Child, Preschool
  • Denosumab / administration & dosage
  • Denosumab / adverse effects*
  • Denosumab / therapeutic use
  • Humans
  • Hypercalcemia / chemically induced*
  • Hypercalciuria / chemically induced*
  • Infant
  • Osteogenesis Imperfecta / drug therapy*
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Denosumab

Supplementary concepts

  • Osteogenesis imperfecta, type 6